Weak start to FY24; Q2 performance holds key Result Synopsis Indoco reported a tepid quarte...
Indoco Remedies is currently trading at Rs. 324.35, up by 1.60 points or 0.50% from its previous ...
Weak set of numbers, outlook upbeat... About the stock: Indoco manufactures and mark...
Indoco Remedies is currently trading at Rs. 330.00, up by 1.10 points or 0.33% from its previous ...
BUY intact even keeping expectation modest Result Synopsis Indoco reported a miss...
Indoco Remedies is currently trading at Rs. 335.75, up by 2.20 points or 0.66% from its previous ...
Indoco Remedies is currently trading at Rs. 338.95, down by 3.50 points or 1.02% from its previou...
Indoco Remedies is currently trading at Rs. 327.00, up by 5.55 points or 1.73% from its previous ...
Temporary hiccup; BUY thesis intact Result Synopsis Indoco clocked a weak quarter...
Azopt profit share yet to kick in; maintaining a Buy Backed by good formulations growth in reg...
Growth thesis intact; valuation attractive Result Synopsis Indoco reported a steady quarter...
Indoco Remedies is currently trading at Rs. 355.15, up by 0.65 points or 0.18% from its previous ...
Indoco Remedies is currently trading at Rs. 381.80, up by 2.95 points or 0.78% from its previous ...
Indoco Remedies is currently trading at Rs. 375.75, up by 1.15 points or 0.31% from its previous ...
Growth expectation intact Result Synopsis Result Synopsis Indoco delivered better than expe...
Indoco Remedies is currently trading at Rs. 368.45, up by 16.25 points or 4.61% from its previous...
Indoco Remedies is currently trading at Rs. 369.05, up by 21.80 points or 6.28% from its previous...
A temporary hiccup; better placed in 4Q and beyond Our view High input costs finally ...
Stellar numbers, margins in Q1… About the stock: Indoco manufactures and markets brande...
Our Take: Indoco Remedies has presence across domestic market, US and EU markets and Emerging ...
Key MeetingTakeaways Ophthalmic products: * The company has 13-14 Ophthalmic ANDAs pending ...
Strong management guidance, execution remains key Q4FY21 revenues grew 12.2% YoY to | 305 cror...
Below are Quote on Indoco Remedies - 4QFY21 by Mr. Yash Gupta Equ...
The company reported standalone net profit of Rs 24.91 crore for the quarter ended March 31, 2021...
Q3 FY21 call highlights * Indoco has received USFDA approval for an injectables product. ...